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Macrophages have the capacity to rapidly secrete a wide range of inflammatory mediators
that influence the development and extent of an inflammatory response. Newly synthe-
sized and/or preformed stored cytokines and other inflammatory mediators are released
upon stimulation, the timing, and volume of which is highly regulated. To finely tune this
process, secretion is regulated at many levels; at the level of transcription and transla-
tion and post-translationally at the endoplasmic reticulum (ER), Golgi, and at or near the
cell surface. Here, we discuss recent advances in deciphering these cytokine pathways in
macrophages, focusing on recent discoveries regarding the cellular machinery and mecha-
nisms implicated in the synthesis, trafficking, and secretion of cytokines.The specific roles
of trafficking machinery including chaperones, GTPases, cytoskeletal proteins, and SNARE
membrane fusion proteins will be discussed.
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INTRODUCTION
Macrophages activated by contact with pathogens or danger sig-
nals release cytokines and chemokines as a major component of
the innate immune response (1). Inflammatory cytokines recruit
other immune cells and orchestrate the actions and fates of the cells
secreting them and those in the surrounding milieu. Macrophages
are one of the most abundant sources of inflammatory cytokines,
which normally act in a protective manner; however, these same
cytokines underlie many acute and chronic inflammatory dis-
eases. Increasingly, it emerges that macrophages secrete cytokines
inappropriately in an ever broadening array of chronic condi-
tions, from diabetes and obesity to vascular and neurodegenerative
diseases (2–4). Many of the newer therapeutics target cytokines
directly, their modes of release, or receptor engagement.
Macrophage cytokines are synthesized and released in response
to activation of pattern recognition receptors or inflammasomes,
and there is an abundant literature documenting the many fac-
tors, signaling cascades, and transcriptional machinery that lead
to cytokine synthesis (5–7). The subsequent organelles, secretory
pathways, and cellular machinery that transport cytokines through
the cell are also critical for ensuring timing and site of release for
new cytokines. These pathways and their regulators will be the sub-
ject of this review. In particular we focus on two large families of
trafficking regulators that guide cytokine secretion through mul-
tiple intracellular steps, the Rab small GTPases, and the SNAREs
(Soluble NSF Attachment Protein Receptors).
CYTOKINE TRAFFICKING PATHWAYS
Cytokine secretion pathways are often adapted to suit specific
cytokines, their function, and cell type. Many immune cells stock-
pile cytokines in distinct compartments – namely, secretory gran-
ules or lysosome-related organelles (LROs) – that enable rapid
release of the cytokines upon cell activation (8, 9). Macrophages,
however, lack these granules, and instead cytokines must be syn-
thesized after cell activation and secreted via the constitutive (or
continuous) secretory pathway or via non-conventional secretion.
The majority of cytokines in macrophages are processed and trans-
ported through the constitutive pathway (10–13) (Figure 1). To
accommodate the need to transport and release large volumes
of cytokines in the first hours after cell activation, the cellular
machinery and carriers involved in the constitutive pathway are
upregulated (11, 12, 14–16) (Table 1). Much of our knowledge
of this pathway comes from work in other cell types, such as
epithelial cells, in addition to studies in macrophages themselves.
Multiple cell types have in common routing of newly synthe-
sized proteins from the endoplasmic reticulum (ER) to the Golgi
complex, sorting in the trans-Golgi network TGN and then for
some cargo, transport directly to the cell surface or transit via
recycling endosomes (17, 18). Much less is known about the non-
classical secretory pathways for cytokine secretion. IL-β and IL-18
are cytokines secreted from the cytoplasm by non-classical path-
ways, although the exact route of release is contentious and might,
in some cases, be cell type specific.
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FIGURE 1 | Classical transport pathways used to secrete macrophage
cytokines. Three major transport pathways for cytokine secretion have
been identified to date. The first involves direct transport to the cell surface
(IL-10) from the TGN, the second pathways routes cytokines via the
recycling endosome and the out to the cell surface (TNF, IL-6, and IL-10),
and the 3rd pathway occurs during phagocytosis where cytokine (TNF) is
routed from the recycling endosome to the phagocytic cup.
CONSTITUTIVE SECRETION OF CYTOKINES
Cytokines such as IL-2, 3, 6, 10, 12 and TNF contain a signal pep-
tide targeting them to the ER, where once correctly folded, they are
packaged into coat protein complex II (COPII) coated vesicles and
delivered to the ER–Golgi intermediate compartment (ERGIC)
and the cis side of the Golgi complex. From here, they are trans-
ported through the medial-Golgi to the TGN, a tubular network
that emanates from the stacked reticulated ribbon-like structured
Golgi cisternae. In addition to the final modifications, proteins
might receive in the TGN, this compartment acts as one of the
major organizing centers to sort cargo to different post-Golgi car-
riers and routes (17). This includes the sorting of transmembrane
cytokines, such as TNF, and less obvious sorting – but certainly
packaging – of soluble cytokines such as IL-6 and IL-10. Other
cargo is also segregated at the TGN, including, glycosyl phos-
phatidyl inositol (GPI)-anchored proteins and lysosomal enzymes
with mannose-6-phosphate tags.
Newly synthesized proteins, recycling, and endosomally derived
proteins all converge at the TGN as cargo requiring packaging into
carriers for post-Golgi transport. Several types of pleomorphic
membrane-bound carriers, which can appear as tubules or vesicles
and often do not have definable coats, exist within the constitutive
secretory pathway. Carrier loading, formation, and transport from
the TGN occur in distinct steps. Firstly, cargo must be segregated
from resident Golgi proteins and sorted into budding carriers. At
exit points on the TGN membrane, a complex array of machin-
ery governs membrane curvature and fission of budding vesicles
or tubules, which then use motors to attach to microtubules for
transport. Imaging in live macrophages shows that cytokines at
the TGN are loaded into tubular or pleomorphic vesicular carriers
and the number of carriers forming can be enhanced to accommo-
date the increased flow of cargo, including cytokines, in activated
cells (14, 15).
For many cytokines, the TGN sorting mechanisms are unknown
or not well defined. In general, the sorting of transmembrane
Table 1 | Proteins and lipids altered by LPS stimulation.
Organelle Protein/lipid Proposed function Reference
ER iRhom2 Promotes TACE exit from the ER (19)
TGN PtdChol Lipid raft/vesicle biogenesis (20)
TGN CCTα Catalyzing PtdChol biosynthesis (20)
TGN p230 Sorting at the TGN (14)
TGN Rab6 Recruitment/stabilization of p230
on TGN membranes
(15)
TGN Stx6 Fusion of TGN-derived vesicles
with recycling endosome
(12)
TGN Stx7 Fusion of TGN-derived vesicles
with recycling endosome
(12)
TGN Vti1b Fusion of TGN-derived vesicles
with recycling endosome
(12)
TGN SCAMP5 Forms a complex with Stx6 and
potentially regulates fusion
with RE
(21)
RE VAMP3 Fusion of TGN-derived vesicle
with RE and the RE with PM
(11)
RE Rab11 Fusion of RE with PM (11)
RE Rab37 Fusion of RE with PM (16)
PM Stx4 Fusion of RE with PM (22)
PM SNAP23 Fusion of RE with PM (22)
PM SCAMP5 Forms a complex with
Stx4/SNAP23 to regulate
exocytosis
(21)
ER, endoplasmic reticulum; TGN, trans-Golgi network; RE, recycling endosome;
PM, plasma membrane.
proteins occurs via adaptor recognition of sorting motifs in their
cytoplasmic tails or by clustering of cargo proteins in distinct
membrane domains such as lipid rafts. ARF and Rab GTPase
family members, adaptors, golgins, and lipids, such as phospho-
inositides, sphingolipids, and cholesterol, all contribute to cargo
sorting and carrier loading at the TGN (17) (Table 2). How sol-
uble cargo, including soluble cytokines such as IL-6 or IL-10, is
sorted is still not clear. The transmembrane cytokine TNF is gen-
erally sorted into specific carriers, while soluble cytokines often
appear in more than one carrier type and exit via more than one
pathway. The latter is suggestive of less stringent or perhaps even
no effective sorting, of soluble cytokines. While the transmem-
brane protein TNF is delivered to highly specific sites on the cell
surface, the surface delivery sites for release of soluble cytokines
may be less regulated. Tubular or vesicular carriers move along
microtubule tracks to their destinations. In addition to their cargo,
carriers must also be loaded with the necessary machinery for
their docking and fusion at the target membrane – steps that
frequently involve specific members of the Rab family of small
GTPases and of the SNARE family of membrane fusion proteins
(Figure 2).
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Table 2 |Trafficking machinery that regulate cytokine secretion in
macrophages.
Protein TNF IL-6 IL-10 Reference
iRhom2 + NA NA (19)
p230 + + + (14)
Golgin-97 − − + (13)
CCTα + + ND (20)
PI3K p110δ + ND − (23)
Dynamin 2 + ND ND (23)
Stx4 + ND + (22)
Stx6 + + + (12)
Vti1b + + + (12)
VAMP3 + + + (11)
SNAP23 + ND + (22)
SCAMP5 + + ND (21)
Rab6 + ND ND (15)
Rab11 + ND + (11)
Rab37 + ND ND (16)
Munc13-1 + ND ND (16)
AP-1 + ND ND (24)
Syt XI + + ND (25)
PKA ND ND + (13)
Rac1 + ND ND (26)
CDC42 + ND ND (26)
NA, not applicable; ND, not determined.
FIGURE 2 |Trafficking machinery regulating specific cytokine transport
steps in macrophages is shown. The transport machinery that regulates
the three major transport steps is shown.
MEMBRANE FUSION AND MAPPING PATHWAYS WITH SNAREs AND
Rabs
Members of the SNARE family are in general ubiquitously
expressed, with the exception of two neuronal specific SNAREs,
Stx1, and SNAP25, and the immune specific SNARE Stx11 (27,
28). Each SNARE operates in one or more defined membrane
locations, which can differ depending on cell type. They form the
minimal machinery required for membrane fusion and loss of
any one component of a specific trans-SNARE complex inhibits
FIGURE 3 | Schematic showing the basic steps in SNARE-mediated
secretion is shown. An R-SNARE on the donor membrane comes together
with a Q-SNARE complex, consisting of two to three Q-SNAREs, on the
target membrane to form a trans-SNARE complex. This brings the two
membranes into close proximity leading to the formation of a fusion pore
allowing the release of some or all of the contents of the vesicle. The pore
can either close (“kiss and run”) or as depicted above the membrane can
fully fuse thus incorporating all of its membrane-associated proteins into
the target membrane. This basic process is same in all cell types and at
different stages of the transport pathways. What differs is the precise
SNARE partners at these distinct stages.
fusion at distinct sites in the cells (29, 30). For example, dele-
tion or mutation of VAMP3, a recycling endosome SNARE, will
inhibit secretion of pathways that require this SNARE for delivery
of recycling endosome membrane to the cell surface (11, 31, 32).
Thus, SNAREs have been employed to map a number of cytokine
secretion pathways in macrophages and many other cell types.
SNARE proteins are mostly transmembrane proteins, with only
a few of them existing as peripheral membrane proteins, anchored
to membrane lipids by post-translational modifications and/or
through protein–protein interactions. Membrane anchored het-
erologous SNAREs from opposing membranes form a tight four-
helix bundle,where each helix is contributed by one of four SNARE
motifs, which act to pull the two membranes into close proximity
(30, 33) (Figure 3). The energy released when the membrane-
bridging (trans-) SNARE complex forms initiates the formation
of a fusion pore between the two opposing membranes. Cargo (or
a portion of it) is discharge through this opening, which might
subsequently close in a process known as “kiss and run exocy-
tosis,” or alternatively, the whole vesicle can fully fuse, merging
transmembrane proteins and lipids into the target membrane and
fully releasing its lumenal contents (34, 35). In the latter case,
membrane and resident proteins – importantly including incom-
ing SNAREs – are then retrieved by endocytosis, which in the
case of macrophages is especially important as large quantities of
membrane are turned over at cell surface during processes such as
macropinocytosis and phagocytosis.
SNARE subtypes have been described based on their central
amino acid, a glutamine (Q-SNARE) or an arginine (R-SNARE).
Based on the position of their SNARE motif in the trans-SNARE
four helix bundle, Q-SNAREs are further partitioned into one
of four subgroups: Qa, Qb, or Qc or, in the case of SNAREs
like SNAP23 that contribute two SNARE motifs, Qb,c (36, 37).
Thus, a trans-SNARE complex consists of one R-SNARE and Q-
SNARE complex, comprising two to three Q-SNAREs (Qa, Qb,
and Qc or Qa and Qb,c), which are typically found on opposing
membranes. The specificity of SNARE pairing to form individual
complexes is in part dictated by the locations of family members.
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After fusion, the SNARE complex then resides in the donor mem-
brane and its subunits must be rapidly disassembled by the ATPase
NSF with its cofactor SNAP, and recycled to their original sites for
further use (38).
Over 60 mammalian members of the small GTPase family of
Rabs help to regulate trafficking at multiple steps through traf-
ficking pathways [reviewed in Ref. (39, 40)]. Like other GTPases,
Rabs switch between an inactive GDP-bound form (in the cyto-
plasm) and an active GTP-bound form (on membranes). The Rab
cycle and nucleotide switching is aided by a host of accessory
proteins. Rabs have varied roles in trafficking through effectors
that can include phosphoinositide-modifying enzymes, budding
machinery, molecular motors, tethering factors, and SNAREs (41–
43). Through tethering effectors, Rabs orchestrate the docking and
tethering of vesicles prior to SNARE-mediated fusion on sequen-
tial organelles in transport pathways. Experimentally, Rabs can be
assigned to transport steps through the actions of GDP- and GTP-
bound functional mutants, through deletion or genetic mutation
of Rab genes, including those associated with human disease.
Macrophages have a rich array of Rabs and many of their immune
functions include regulation by Rab cascades. Notably also, key
Rabs are targeted by bacterial effectors of intracellular pathogens.
Molecular regulators, like the Rabs and SNAREs that are found
throughout the different trafficking pathways, offer many poten-
tial targets for therapeutic intervention, although inflammation
has not yet directly benefited from these approaches (44). SNAREs
are notably inactivated by botulinum and tetanus toxins and the
therapeutic potential for this approach in wide ranging conditions
is actively pursued (45). Rab proteins are also considered as attrac-
tive therapeutic targets, including via prenylation inhibitors (46).
Future studies will no doubt increasingly explore some of these
solutions for controlling cytokine secretion.
TNF SECRETION
SORTING AND TRANSPORT OF TNF
TNF mRNA is constitutively expressed and controlled by mRNA
stability and translation. Activation leads to its rapid transcription,
generating a type II membrane protein that can be found in the
macrophage Golgi complex soon after LPS-activation (47). TNF
is then packaged exclusively into a population of TGN-derived
tubules/vesicles labeled with the GRIP-golgin p230/golgin245
(14). The GRIP-domain golgins are located on distinct TGN
domains and regulate trafficking to and from the TGN. Four mam-
malian GRIP-golgins exist on the TGN, namely p230, CCC88,
GCC185, and golin-97, and all share a TGN targeting GRIP
domain in their c-terminus (48). What is notable is that in the
absence of LPS, similar numbers of p230 and golgin-97 labeled
tubules/carriers exit the TGN but upon activation with LPS
the p230-labeled tubules are selectively upregulated threefold to
enhance cytokine transport (14).
The p230-labaled TNF carriers are also regulated by Rab6 and
Rab6a′, which act to stabilize Arl1-recruited p230 on TGN mem-
branes (15). The Rab6 isoforms are quintessential Golgi-associated
Rabs and both participate in multiple steps of trafficking through
several effectors. Myosin IIA is a Rab6 effector on the p230-
labeled tubules that move TNF and other cargo from the TGN
to recycling endosomes (49). Rab6, like other Rabs involved in the
macrophage constitutive pathway, is upregulated by LPS, offering
more transport capacity in activated cells.
Lipids and phospholipids at the TGN are also regulated for
trafficking. Despite the preponderance of PI4P in Golgi mem-
branes, a number of PI3 kinases regulate budding and vesicle
exit from the TGN (50). Among them, PI3Kδ is found on TGN
membranes, where it and dynamin II, regulate TNF trafficking
and TGN exit (23). The GTPase dynamin II functions in fission
of clathrin-coated and non-clathrin-coated vesicles and carriers
at the Golgi and on other membranes (51). A number of lipid
metabolic genes are also upregulated in response to LPS, includ-
ing choline cytidylyltransferase alpha (CCTα), phospholipase D1
(PLD1), and the choline/ethanolamine phosphotransferase C/EPT
(20). Lipids play an active role in the biogenesis of carriers and in
organizing TGN exit domains (20). Thus, localized changes in
lipid composition can greatly alter secretion by recruiting specific
proteins and promoting membrane fission or fusion. CCTα, a key
enzyme catalyzing PtdChol biosynthesis in macrophages, regu-
lates vesicle formation and budding (20). Its inactivation reduces
PtdChol synthesis leading to decreased TNF secretion suggesting
that PtdChol and CCTα are also critical for transport from the
Golgi complex (20). Thus, the upregulation of lipid machinery
also enhances the export of TNF from the TGN.
TGN carriers transport TNF and other cargo to recycling endo-
somes as a second transit and sorting station. This transport is well-
defined through identification of the relevant SNAREs (11, 12).
The Q-SNARE complex Stx6/Stx7/Vti1b is packaged with TNF
into TGN-derived vesicles and upon reaching the recycling endo-
some, this Q-SNARE complex pairs with the resident R-SNARE
VAMP3 for fusion (11, 12). The members of this SNARE complex
are upregulated and packaged into the TGN-derived vesicles in
response to LPS to accommodate the increased number of p230
requiring fusion with the recycling endosome (11, 12). On-going
transport to the cell surface requires the recycling endosomes, or
tubular extensions of this compartment bearing VAMP3, to fuse
with the plasma membrane, via the cell surface Q-SNARE complex
of Stx4/SNAP23 (11, 22). This step of the constitutive pathway, like
earlier stages, is also enhanced in activated macrophages by upreg-
ulation and increased levels of the cell surface SNAREs (11, 22).
Loss or inactivation of any of these SNARE components blocks
TNF secretion.
The location of the surface SNARE complex plays a key role
where TNF secreted. Surface SNAREs, such as Stx4 are clustered in
cholesterol-rich lipid rafts, which adorn filipodia and phagocytic
cups on the surface of activated macrophages (52). Disruption of
these lipid rafts reduces TNF secretion (52). Macrophages use their
filopodia to explore their environment and capture pathogens; this
binding leads to filopodia retraction and pseudopod formation
from the underlying lamellipodia to form the phagocytic cup (53).
Stx4 translocates and concentrates on these lipid rich pseudopods
and regulates the focal fusion of the recycling endosome with
the phagocytic cup (11, 52). This serves two purposes; provid-
ing extra surface membrane necessary for macrophages to engulf
microbes while simultaneously delivering TNF to the pseudo-
pod tips for rapid secretion (11, 52). Stx4 is then removed, and
presumably recycled to the cell surface, after the phagosome is
internalized (11, 52).
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Two Rab GTPases, Rab11 and Rab37, have been found to reg-
ulate surface delivery of TNF (11, 16) and these Rabs are also
upregulated after LPS activation of cells. Rab11 is a well-known
marker of recycling endosomes, where it mediates transport to
the cell surface and similarly participates in the delivery of TNF
through recycling endosomes to the plasma membrane. Rab37 is
also located on the TNF-loaded vesicles that fuse with the plasma
membrane. Intriguingly, in macrophages Rab37 associates with
Munc13-1, a diacylglycerol, calcium, and calmodulin activated SM
family protein, known to be required for synaptic vesicle prim-
ing and for insulin release in pancreatic beta cells (16). Loss of
Munc13-1 or Rab37 reduced TNF secretion (16).
Adaptor proteins regulate sorting of membrane proteins and
the AP-I complex has been implicated in both phagocytosis and
the trafficking of TNF from the recycling endosome (24). Typi-
cally, AP complexes recruit the coat protein clathrin to vesicles for
their formation, but this is not the case during phagocytosis where
AP-1 decorated endosomes amass below the phagocytic cup in an
ARF-1-dependent, clathrin-independent manner (24). Depletion
experiments suggest that AP-1 might act to sort TNF at the recy-
cling endosome and a cleaved form of AP-1 accompanies carriers
that bud off the recycling endosome to the surface for VAMP3-
and ARF6-dependent delivery at the tips of pseudopodia during
phagocytosis (54, 55).
The protein trafficking machinery described above largely reg-
ulates discrete stages of TNF secretion, but this may not be the
case for all trafficking machinery. Secretory carrier membrane
proteins (SCAMPs) are found in complexes with SNARE proteins
and regulate exocytosis (21). In macrophages, SCAMP5 expres-
sion is upregulated by Toll-like receptors (TLR) agonists like LPS
and by increases in intracellular calcium through stimulation with
ionomycin (21). Both stimuli result in SCAMP5-dependent TNF
secretion (21). SCAMP5 has the potential to regulate SNAREs
at multiple points in the TNF secretory pathway and can form
complexes with many of the SNAREs (Stx4, Stx6, SNAP23, and
VAMP3) identified at the different stages of TNF secretion (21). In
the absence of stimulus, SCAMP5 localizes predominantly to the
Golgi complex along with Stx6 and after stimulation with iono-
mycin shifts to the recycling endosome and cell surface, where it
colocates with Stx4/SNAP23 (21). This shift in localization occurs
in parallel to TNF secretion (21). Although SCAMP5 forms a com-
plex with SNARE proteins, this binding is not direct and occurs
through the calcium binding transmembrane synaptotagmins
(Syt) (21). Loss of the synaptotagmin-binding site in SCAMP5
inhibits ionomycin induced TNF secretion (21). SCAMP5 binds
at least two synaptotagmins, Syt1 and Syt II, but their role in TNF
has yet to be established.
However, other synpatotagmins play a role, or have been impli-
cated in, TNF secretion. Syt V is located on recycling endosomes
and filopodia-like structures and is recruited to the nascent phago-
some (56). It has a role in the recruitment of recycling endosomes
to the phagocytic cup, and its loss impairs phagocytosis suggesting
that it might also positively regulate TNF secretion (56).
While Syt V’s role in TNF secretion has not been tested directly,
another synaptotagmin, Syt XI, located on recycling endosomes
and recruited to phagosomes, has been found to inhibit TNF secre-
tion. Its role in inhibiting cytokine secretion suggests that members
of this family of proteins might play an important role in regulat-
ing different aspects of cytokine secretion (25). Syt XI is one of the
few family members that does not bind calcium and unlike most
family members, it inhibits vesicle fusion by an unknown mecha-
nism but one that could be focused on inhibiting SNARE function.
Syt XI also inhibits IL-6 secretion, whose trafficking diverges from
TNF at the level of the recycling endosome, suggesting that Syt XI
might function prior to surface delivery. Taken together, protein
families, like SCAMPs and synaptotagmins, functioning along-
side SNAREs, also clearly participate in cytokine release at or near
surface domains.
Rho GTPases act as molecular switches, that cycle between
GTP-bound inactive and GDP-bound inactive states, to regulate
remodeling of the actin cytoskeleton in cellular processes such as
adhesion, migration, and membrane trafficking. Rac1 and CDC42
regulate the cell surface leading to the formation of lamellipodia
and smaller filapodia, respectively, and also play a role in regulat-
ing organelle movement (57, 58). In LPS stimulated macrophages,
these two Rho GTPases are essential for efficient surface delivery
of TNF (26). In the absence of Rac1 function in particular, TNF
is synthesized and is held up in recycling endosomes along with
other endosomal cargo such as transferrin (26). These results sug-
gest that Rac1 is involved in the final stages of TNF transport to the
cell surface, possibly through the positioning or surface delivery
of TNF-loaded recycling endosomes.
TACE-MEDIATED RELEASE OF SOLUBLE TNF
Once incorporated into the cell surface, membrane anchored TNF
is cleaved by the ADAM family metalloproteinase TNF-converting
enzyme (ADAM17 or TACE) at a site after alanine 76, to release
the soluble active TNF ectodomain. Both transmembrane pro-
teins, TACE and TNF (proprotein) can be organized by lipid raft
domains on the cell surface (52). In different cell types and con-
texts, TACE can be found sequestered in lipid rafts or in non-raft
fractions. In macrophages, TACE appears primarily in non-raft
fractions, whereas TNF is delivered initially to lipid rafts in the
plasma membrane where the Stx4 Q-SNARE complex is enriched
for membrane fusion (52, 59). TNF is delivered to nascent phago-
cytic cups, where TACE is also enriched (11, 52). One possible level
of regulation for cytokine release is the movement of TNF out of
lipid rafts to access TACE for cleavage.
The level of TACE at the cell surface is also modulated by
LPS cell activation and by intracellular trafficking machinery (19).
Recently, the intramembrane protease, iRhom2, has been identi-
fied as a key regulator of TACE. Although catalytically inactive,
iRhom2 is a member of the rhomboid family of intramembrane
serine proteases. At the ER, TACE is bound by iRhom2, which pro-
motes its exit from the ER and loss of iRhom2 leads to a build up of
TACE in the ER (19). Both the pro and mature forms of TACE bind
to iRhom2 suggesting that it remains associated through multiple
stages of the secretory pathway (60). Loss or inactivating mutations
of iRhom2 in mice reduce the levels of TNF secreted in response to
LPS challenge (61). These results together suggest that iRhom2 acts
as a cargo receptor or chaperone to aid in the trafficking of TACE
from the ER to the Golgi where furin activates TACE by cleaving its
N-terminal inhibitory domain (19). Like many proteins that reg-
ulate TNF secretion, LPS stimulation upregulates iRhom2 levels,
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permitting increased TACE transport to the cell surface for TNF
cleavage and shedding (19).
INTERLEUKIN 6 SECRETION
Interleukin 6 (IL-6) is another proinflammatory cytokine and an
example of soluble cargo transported through the constitutive
secretory pathway. At the level of the TGN, some IL-6 can be
segregated away from TNF into distinct carriers (10). The rest
appears together with TNF in post-Golgi carriers and in recycling
endosomes (10). Like TNF, IL-6 transport out of the TGN relies on
PtdChol and CCTα (20). The R-SNARE VAMP3 on the recycling
endosome regulates the delivery of Q-SNARE Stx6/Vti1b/Stx7
labeled vesicles containing IL-6 (10).
At the recycling, endosome IL-6 and TNF are segregated
into distinct domains and transported to the plasma membrane
through different routes (10). Exactly how they are sorted in the
recycling endosome is unknown, but it maybe that TNF is actively
sorted away from IL-6 or alternatively both are individually sorted.
Not surprisingly, a number of trafficking machinery proteins that
regulate TNF at the level of the recycling endosome, including
SCAMP5 and Syt XI also regulate IL-6 secretion (21, 25). While
both TNF and IL-6 are delivered to the cell surface, the transport
route for IL-6 from the recycling endosome is multidirectional
even during phagocytosis when TNF is specifically delivered to
the tips of nascent phagosomes for secretion (10).
INTERLEUKIN-10 SECRETION
Interleukin-10 (IL-10) is also a soluble cytokine targeted to the
lumen of the ER by a signal peptide. In RAW cells, IL-10 secre-
tion begins later than that of TNF and IL-6 and persists for longer
(13). Importantly, IL-10 is a regulatory cytokine and one of its
primary effects is to decrease the secretion of TNF and other
proinflammatory cytokines. From the ER, newly synthesized IL-
10 is transported to the Golgi complex where at the TGN, it can
be directed into at least two distinct pathways to the surface, one
direct and the other indirect. The latter pathway carries the bulk
(80%) of IL-10 in the same p230 labeled carriers as IL-6 and TNF
to the recycling endosome, where it is sorted for transport to the
cell surface (13). Depletion or inactivation of p230/golgin245 or
other TGN machinery disrupts IL-10 secretion through this recy-
cling endosome route (13) and the final surface delivery of IL-10
is enacted by Rab11 and VAMP3-positive recycling endosomes,
which fuse with the plasma membrane (13). Thus, there is no
separation of pro- and anti-inflammatory cytokines in terms of
pathways utilized.
In the second secretory pathway, IL-10 is packaged with ApoE at
the TGN into golgin-97 labeled tubules and transported directly
to the cell surface, bypassing the recycling endosome (13). This
ApoE transport pathway is dependent on microtubules and PKA
(13). As a soluble cytokine, IL-10 is likely to be packaged into
multiple routes for TGN exit and surface delivery. Redundancy
in overall pathways, carriers, and molecular regulators for the
secretion of different cytokines, such as IL-6 and IL-10, reflects
the fact that many are soluble proteins, and therefore, handled as
“bulk cargo” by the cell. As a deeper understanding of traffick-
ing emerges, especially in post-Golgi steps, factors such as sorting
receptors, membrane domains, and intraluminal pH, may well be
found to differentiate the final release of soluble cytokines like IL-6
and IL-10.
INTERLEUKIN-1 BETA SECRETION
Members of the IL-1 cytokine family, particularly IL-1β, IL-18, and
IL-37 are key inflammatory cytokines with important roles also in
disease, and with the distinction of using non-classical or uncon-
ventional secretory pathways for their release (62). In macrophages
activated through a TLR, the precursor pro-IL-1β is synthesized
but to fully achieve cytokine release, a second danger signal, for
instance extracellular ATP (63), activates the multisubunit signal-
ing complex of the NLRP3/caspase-1 inflammasome. Activated
caspase-1 proteolytically cleaves pro-IL-1β to produce the mature,
active form of the cytokine that is secreted. Exactly how IL-1β and
other such cytokines find their way out of cells remains a topic of
conjecture and conflicting evidence (62).
Several routes have been championed for the release of cleaved
IL-1β from monocytes/macrophages and in different circum-
stances any or all of these routes may apply. Earlier studies on
human monocytes used inhibitors to implicate the ATP bind-
ing cassette transporter (ABC1) as an exit portal directly through
the plasma membrane for the release of IL-1β (64). The ABC
transporter route has also been demonstrated for other solu-
ble, secreted mediators including macrophage migration inhibitor
factor (MIF) (65). Cell death through pyroptosis and other mech-
anisms may also lead to leakage and release of leaderless cytokines
(66). Unconventional vesicular or organellar pathways have also
been touted. Exosomes, derived either by blebbing of the plasma
membrane or by budding off endosomal/lysosomal compartments
may enfold cytosolic IL-1β for transport out of the cell [reviewed
in Ref. (67)]. Macrophages have secretory lysosomes (68), which
equate in some respects to LROs as dedicated secretory compart-
ments in some other cell types. There is evidence for the transfer
(by an unknown transporter) of leaderless cytoplasmic proteins,
including cytokines (69), into secretory lysosomes for release.
Related organelles, autophagosomes, or autophagolysosmes, have
also been implicated in IL-1β release. While autophagy is primar-
ily a degradative process in the cytoplasm, secretory autophagy is
proposed as a parallel function for unconventional secretion, in
yeast (70) and mammalian cells (71). This secretory autophagy
may contribute transiently to acute release of IL-1β in activated
macrophages, via a pathway that interestingly is mediated by
Atg5, inflammasome, the Golgi reassembly stacking protein 55
(GRASP55) and Rab8a (72). Knockdown of Rab8a reduced the
secretion but not the synthesis of IL-1β (72); moreover, Rab8a
and its close homolog Rab8b have distinct roles in secretory and
degradative autophagy, respectively (71). Further studies are likely
to reveal more of the machinery associated with these unconven-
tional secretory routes, predictably more Rabs, and also possibly
SNAREs for vesicular routes.
OTHER CYTOKINES
To date, little data are available on the trafficking machinery nec-
essary for the secretion of many of the cytokines secreted by
macrophages. For some, it has been shown specific subunits or
receptors can chaperone cytokines through the secretory pathway.
IL-15 and IL-12 are two such cytokines. IL-12 is a proinflammtory
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cytokine that controls the differentiation of naïve T cells into IFN-
γ-producing Th1 cells and plays key a role in the development of
autoimmune diseases and in the pathology associated with inflam-
matory related disease such as psoriasis (73). The bioactive form of
IL-12, known as p70, is composed of two subunits, P35 and p40,
with the availability of p35 being the major determining factor
in its secretion (74). P35 is regulated at both transcriptional and
post-transcriptional levels, and like p40 contains a signal peptide
that targets it to the ER (75). However, in contrast to p40 whose
signal peptide is removed during translocation into the ER, the
p35 signal peptide is cleaved in an unconventional manner (75).
Within the ER, a primary intermediate cleavage occurs, followed
by a second cleavage before or immediately after exit from ER (75).
Once in the ER p35, an integral membrane protein, binds to sol-
uble p40 subunit to form membrane anchored p70 heterodimer,
which then leads to its transport through the Golgi complex to the
cell surface (76).
IL-15 plays an important role in regulating the activity and per-
sistence of a large variety of cell types. Much of the work on IL-15
secretion has been undertaken in other cell types where its secre-
tion, via the ER and Golgi complex, is dependent on its cognate
receptor, the IL-15 receptor α (IL-15Rα), which acts as a chaper-
one enabling IL-15 to exit the ER and traffic through the secretory
pathway (77). In macrophages, IL-15Rα is upregulated by IFNγ
treatment, leading to secretion of IL-15, suggesting that a simi-
lar chaperone mechanism might occur (77). IL-15Rα contains a
nuclear export sequence and can also be transported to the cell
surface via the nucleus along with IL-15 in a chromosomal region
maintenance 1 (CRM1) dependent manner (78). ARF6 has also
been shown to promote IL-15 secretion, although exactly how is
not clear (78).
The DNA binding nuclear protein high-mobility group box
1 protein (HMGB1) has multiple roles including being a potent
mediator of inflammation (79). Extracellular HMGB1 acts as a
proinflammatory alarmin or DAMP (damage-associated molec-
ular pattern) that regulates inflammation through its binding to
TLR 2, TLR4, and TLR9, to CD42 and to the advanced gylcation
end product receptor (RAGE) (79). It can be released passively
during necrosis (80) or actively through at least one non-classical
secretory pathway (72, 81). Secretion begins around 6 h post-
stimulation with levels still increasing 30 h later suggesting that it
has a “late” role in regulating inflammation (81). Lacking a secre-
tory signal peptide, HMGB1 is not targeted to the ER and Golgi
complex. It does possesses a nuclear localization signal (NLS) and
two non-classical nuclear export signals (NES) that regulate its
shuttling between the cytosol and nucleus, with its equilibrium
almost completely shifted toward nuclear accumulation in unac-
tivated monocytes and macrophages (82). On activation, phos-
phorylation and acetylation of HMGB1 target it to the cytosol
and partially into lysosomes from where it can be secreted (81,
82). The trafficking machinery that regulate this pathway and its
release from cells are unknown, although in cancer cells HMGB1
is found in a complex with Annexin A2, myosin IC isoform a,
myosin 9, and Rab10, suggesting that these proteins might play
a role in its release (83). In macrophages, the same autophagy-
based unconventional secretion pathway that releases IL-1β can
also secrete HMGB1 and accordingly its release has the potential
to be regulated by Atg5, the inflammasome, the Golgi reassembly
stacking protein 55 (GRASP55), and Rab8a (72). Thus HMGB1
might be released by two different routes, although whether this
occurs simultaneously or under distinct circumstances is yet to be
determined.
CONCLUSION
The sequential and temporally orchestrated nature of cytokine
secretion limits the demand for increased secretion to distinct
times of need. It is becoming increasingly clear that upon LPS-
activation macrophages adapt to this mandate by resourcefully
modifying the levels or location of specific trafficking machin-
ery molecules. This bolsters the sorting of cargo at the two major
sorting hubs – the TGN and recycling endosome – and acceler-
ates the passage of cytokines through distinct transport pathways.
Although cytokine trafficking has not directly been compared in
macrophages under different activation regimes, the overlapping
pathways used to traffic IL-10 compared to IL-6 for instance,would
suggest that both M2 and M1 polarized cells have largely common
secretory pathways.
The adaptations for some of the cytokine trafficking pathways
are strategic, such as the routing of recycling endosome mem-
brane containing TNF to the phagocytic cup during times of
infection. This clever strategy allows the concomitant release of
TNF and provides extra membrane for phagocytic cup forma-
tion processes. Other adaptations might allow the packaging of
cytokines into more than one pathway for rapid release. Whether
non-classical secretory pathways are similarly modified during
infection is unknown, but answering this along with further elu-
cidation of the classical pathways and machinery might in future
allow the targeted intervention in inflammatory diseases where
excessive cytokine secretion is a major determining factor.
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